Given Imaging Ltd, (Nasdaq:GIVN), a world leader in
gastrointestinal medical devices and pioneer of capsule endoscopy,
today announced that more than 150 studies confirming the value of
Given Imaging's portfolio of extensive products in detecting and
monitoring gastrointestinal diseases will be presented during the
upcoming American College of Gastroenterology (ACG) 2013 Annual
Scientific Meeting and Post Graduate Course and United European
Gastroenterology Week (UEG Week).
"With the approval of PillCam COLON and PillCam SB 3 in Japan
and the clearance of PillCam SB 3 in the U.S., 2013 has been a
milestone year for Given Imaging. We expect this momentum to
continue to be fueled by positive data presented at these
conferences confirming existing and new product indications," said
Homi Shamir, president and CEO, Given Imaging. "A wide range
of data, including ten PillCam COLON studies, underscore our
leadership in detecting and monitoring GI diseases, including
colorectal cancer, Crohn's disease, obscure GI bleeding and
gastroparesis."
The 2013 American College of Gastroenterology Annual
Scientific Meeting
Given Imaging will be at booth #1200 at ACG taking place October
11 - 16, 2013 in San Diego, California. Key abstracts being
presented during the meeting include:
PillCam® SB capsule endoscopy:
- "Capsule Endoscopy (CE) Can Improve Outcomes in Crohn's
Disease: An Evaluation of Pre- and Post-treatment CE"
(poster 426) presented by Dr. Neel K. Mann and Dr. Simon Lo on
Sunday, October 13 from 3:30 – 7 p.m. PDT.
Bravo® pH-monitoring:
- "Four-Day Two-Phase Wireless pH Monitoring for
Evaluation of Esophageal Symptoms Refractory to High Dose PPI:
Utility in Clinical Practice" (poster 14) presented by Dr.
Louis Wilson on Sunday, October 13 from 3:30 – 7 p.m. PDT.
SmartPill® motility monitoring:
- "Clinical Utility and Diagnostic Yield of 165 Wireless
Capsule Studies at a Tertiary Referral Center" (poster
1684) presented by Dr. Zubin Arora on Tuesday, October 15 from
10:30 a.m. - 4 p.m. PDT.
ManoScan® high resolution manometry:
- "Alterations in Esophageal Function on High Resolution
Esophageal Manometry in the Elderly" (poster 1216)
presented by Dr. Stephanie Worrell on Tuesday, October 15 from
10:30 a.m. - 4 p.m. PDT.
United European Gastroenterology Week 2013
Given Imaging will be at booth #7 located in Hall 15.1 at UEG
Week taking place in Berlin, Germany October 12-16, 2013. Key
abstracts being presented during the meeting include:
PillCam® COLON capsule endoscopy:
- "Colon Capsule Endoscopy Versus CT-Colonography In The
Evaluation Of Patients With Incomplete Traditional Colonoscopy: A
Prospective Comparative Trial" (oral presentation 431)
presented by Dr. Cristiano Spada on Wednesday, October 16 from noon
- 12:12 p.m. CEST.
- "French Multicenter Experience of Colon Capsule
Endoscopy in Real Practice: Primary Results of the Colon Capsule
Endoscopy Observatory "ONECC"" (poster1337) presented by
Dr. Jean-Christophe Saurin on Wednesday, October 16 from 9 a.m. – 5
p.m. CEST.
PillCam® SB capsule endoscopy:
- "Why Should We Still Use Capsule Endoscopy In
Inflammatory Bowel Diseases?" (oral presentation 430)
presented by Dr. Lucia Marquez on Wednesday, October 16, 2013 from
11:48 a.m. – noon CEST.
Bravo® pH monitoring:
- "The Real Prevalence Of Functional Heartburn: The
Lesson Of Prolonged Wireless pH Monitoring" (poster 1598)
presented by Dr. Roberto Penagini on Wednesday, October 16 from 9
a.m. – 5 p.m. CEST.
ManoScan® high resolution manometry:
- "Prevalence Of Relaxation Disorders Of The Lower
Esophageal Sphincter In Patients Undergoing High-Resolution
Manometry" (poster 1585) presented by Dr. Jutta Keller on
Wednesday, October 16 from 9 a.m. – 5 p.m. CEST.
About Given Imaging Ltd.
Since pioneering the field of capsule endoscopy in 2001, Given
Imaging has become a world leader in GI medical devices, offering
health care providers a range of innovative options for
visualizing, diagnosing and monitoring the digestive system. The
company offers a broad product portfolio including PillCam® capsule
endoscope for the small bowel, esophagus and colon. The company
also offers industry-leading GI functional diagnostic solutions
including ManoScan® high resolution manometry, Bravo® capsule-based
pH monitoring, Digitrapper® pH-Z monitoring, and SmartPill®
motility monitoring systems. Given Imaging is committed to
delivering breakthrough innovations to the GI community and
supporting its ongoing clinical needs. Given Imaging's headquarters
are located in Yoqneam, Israel, with operating subsidiaries in the
United States, Germany, France, Japan, Australia, Vietnam, Hong
Kong and Brazil. For more information, please visit
givenimaging.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, projections about our
business and our future revenues, expenses and profitability.
Forward-looking statements may be, but are not necessarily,
identified by the use of forward-looking terminology such as "may,"
"anticipates," "estimates," "expects," "intends," "plans,"
"believes," and words and terms of similar substance.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual events,
results, performance, circumstances or achievements of the Company
to be materially different from any future events, results,
performance, circumstances or achievements expressed or implied by
such forward-looking statements. Such forward-looking statements
include statements relating to the Company exploring strategic
alternatives and considering possible strategic transactions
involving the Company. Factors that could cause actual events,
results, performance, circumstances or achievements to differ from
such forward-looking statements include, but are not limited to,
the following: (1) our ability to develop and bring to market new
products, (2) our ability to successfully complete any necessary or
required clinical studies with our products, (3) our ability to
receive regulatory clearance or approval to market our products or
changes in regulatory environment, (4) our success in implementing
our sales, marketing and manufacturing plans, (5) the level of
adoption of our products by medical practitioners, (6) the
emergence of other products that may make our products obsolete,
(7) lack of an appropriate bowel preparation materials to be used
with our PillCam COLON capsule, (8) protection and validity of
patents and other intellectual property rights, (9) the impact of
currency exchange rates, (10) the effect of competition by other
companies, (11) the outcome of significant litigation, (12) our
ability to obtain reimbursement for our product from government and
commercial payors, (13) quarterly variations in operating results,
(14) the possibility of armed conflict or civil or military unrest
in Israel, (15) the impact of global economic conditions, (16) our
ability to successfully integrate acquired businesses, (17) changes
and reforms in applicable healthcare laws and regulations, (18)
quality issues and adverse events related to our products, such as
capsule retention, aspiration and failure to attach or detach,
bleeding or perforation that could require us to recall products
and impact our sales and net income, and (19) other risks and
factors disclosed in our filings with the U.S. Securities and
Exchange Commission, including, but not limited to, risks and
factors identified under such headings as "Risk Factors,"
"Cautionary Language Regarding Forward-Looking Statements" and
"Operating Results and Financial Review and Prospects" in the
Company's Annual Report on Form 20-F for the year ended December
31, 2012. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Except to the extent expressly required under
applicable law, the Company undertakes no obligation to release
publicly any revisions to any forward-looking statements, to report
events or to report the occurrence of unanticipated events.
CONTACT: For further information contact:
Chantal Beaudry/Martyna Gawrych
Lazar Partners Ltd.
cbeaudry@lazarpartners.com
mgawrych@lazarpartners.com
212-867-1762
Investor Contact:
David Carey
Lazar Partners Ltd.
dcarey@lazarpartners.com
212-867-1762
Israel Investor Contact:
Nava Ladin
Gelbart Kahana Investor Relations
+972-3-6074717
nava@gk-biz.com
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Aug 2023 to Aug 2024